Welcome to our dedicated page for Marex Group SEC filings (Ticker: MRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings for Marex Group plc (NASDAQ: MRX), a diversified global financial services platform operating across energy, commodities and financial markets. As a foreign private issuer, Marex files an annual report on Form 20-F and periodic Form 6-K reports that furnish press releases and financial information to U.S. investors.
Recent Form 6-K filings include earnings-related disclosures, such as interim results, third quarter results and preliminary trading updates. These documents provide detail on revenue, adjusted profit before tax, segment performance across Clearing, Agency and Execution, Market Making, and Hedging and Investment Solutions, as well as information on net commission income, net trading income, net interest income and net physical commodities income. They also discuss non-IFRS measures, their definitions and reconciliations to the most comparable IFRS metrics.
Other 6-Ks relate to corporate actions and governance, including press releases about purchases of ordinary shares by the Chief Executive Officer and other directors and officers. These filings help investors track insider share dealings and understand how management and board members are building or adjusting their holdings in Marex.
Filings may also reference capital and ratings developments, such as senior debt issuances, Additional Tier 1 instruments and credit ratings from S&P Global Ratings for Marex Group and its U.S. subsidiary, Marex Capital Markets Inc. Together, these disclosures provide insight into the Group’s capital structure, funding and external credit assessment.
On Stock Titan, Marex’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools can assist users by surfacing key points from lengthy filings, highlighting segment trends, explaining non-IFRS measures and drawing attention to notable items such as insider transactions and earnings commentary, helping readers navigate the technical language common in cross-border capital markets reporting.
Marex Group plc is offering Issuer Callable Fixed Interest Barrier Notes linked to the Worst Performing of the S&P 500, Russell 2000 and Nasdaq-100, maturing June 29, 2027. The Notes pay a fixed quarterly interest of $34.38 per $1,000 (3.438% per quarter, 13.752% per annum) and are callable on quarterly Call Payment Dates beginning September 22, 2026.
The Notes use a 70% barrier (Barrier Values shown) versus Initial Values set on the Pricing Date. If a Trigger Event occurs and the Worst Performing Underlying finishes below its Initial Value, the Payment at Maturity will be $1,000 + ($1,000 × Reference Return of the Worst Performing Underlying), exposing holders to a potential loss up to 100% of principal. The Estimated Initial Value is expected between $985.00 and $995.00 per Note. Terms reference adjustment provisions and observation/valuation date mechanics; see the prospectus supplements for full details.
Marex Group plc is offering Issuer Callable Contingent Income Barrier Notes linked to the worst performing of the Invesco S&P 500® Equal Weight ETF (RSP), the Russell 2000® Index (RTY) and the Nasdaq-100 Index® (NDX).
The Notes have a $1,000 Principal Amount per note, an expected Estimated Initial Value between $990.00 and $998.00, quarterly Contingent Coupons of 3.413% (equivalent to 13.652% per annum) payable only if each Underlying is ≥70.00% of its Initial Value on a Coupon Determination Date, and a Barrier at 65.00% of Initial Value. The issuer may redeem on quarterly Call Payment Dates beginning September 22, 2026. If not redeemed and the Worst Performing Underlying is below its Barrier on the Final Valuation Date, investors bear full downside and may lose up to 100% of principal. All payments are subject to Marex’s credit risk.
Marex Group plc has scheduled a High Court hearing for its scheme of arrangement related to its proposed redomiciliation to Bermuda. The hearing is set for June 26, 2026 at the Royal Courts of Justice in London.
If approved and all conditions are met, the Scheme is expected to become effective on July 1, 2026, when Marex Group plc’s ordinary shares on Nasdaq would be substituted with ordinary shares of Marex Group Limited. The company highlights that these timings are forward-looking and subject to risks and uncertainties.
Marex Group plc officer Paolo Tonucci reported selling 16,666 Ordinary Shares of the company in open-market transactions. The sales took place on June 15, 2026 at weighted average prices around the low $60s, with individual trade prices ranging from $60.945 to $63.075.
The filing notes these trades were executed under a pre-arranged Rule 10b5-1 trading plan entered into on October 22, 2025, indicating they were scheduled in advance. Tonucci’s reported holdings include 220,746 ordinary shares underlying deferred bonus plan awards that convert into one ordinary share each upon vesting and settlement.
Marex Group plc Chief Executive Officer Ian T. Lowitt reported open-market sales of a total of 37,143 Ordinary Shares on June 12, 2026, executed under a pre-arranged Rule 10b5-1 plan. The shares were sold at weighted average prices in the low-$60s per share.
Following these transactions, Lowitt directly holds 2,831,358 Ordinary Shares, which includes 194,411 shares underlying deferred bonus plan awards that represent contingent rights to receive one share each upon vesting and settlement.
MRX affiliate submitted a Form 144 notice to sell Common Stock. The filing lists proposed and recent sales by Paolo Tonucci, including transactions of 16,666–16,668 shares on 02/23/2026, 03/16/2026, 04/13/2026, and 05/11/2026 with reported proceeds shown.
Marex Group plc is offering $300,000 of Autocallable Fixed Income Notes with Absolute Return Buffer linked to the worst performing common stock of Apple (AAPL), Coherent (COHR) and Morgan Stanley (MS). Each Note has a $1,000 principal amount, a quarterly fixed interest payment of $30.00 (3.00% per quarter; 12.00% per annum) and an Estimated Initial Value of $948.90 per Note on the Trade Date. The Notes can be automatically called on specified Call Observation Dates if each underlying closes at or above its Call Threshold; otherwise payment at maturity depends on the Reference Return of the Worst Performing Underlying with a 50.00% buffer and a Downside Leverage Factor of 200%. The offering price to public is $1,000.00 per Note; proceeds to issuer are $975.00 per Note. The Notes are senior unsecured obligations of Marex and are subject to Marex credit risk, limited liquidity, and the detailed risk factors described in the supplement.
MRX: a Form 144 notice lists proposed sales of Common Stock by an issuer insider.
The filing shows proposed sell quantities tied to compensation grants: 29,769 shares with a 03/10/2025 grant date and 7,374 shares with a 05/19/2025. The broker listed is J.P. Morgan Securities LLC.
Marex Group plc is offering Autocallable Fixed Income Notes with Absolute Return Buffer linked to the worst performing of AAPL, COHR and MS. Each Note has a $1,000 principal amount, quarterly fixed interest equal to 3.00% per quarter (12.00% per annum), an expected Estimated Initial Value between $920.00 and $960.00, a Final Valuation Date of December 13, 2027 and a Maturity Date of December 20, 2027.
The Notes pay quarterly interest and are subject to an automatic call if each Underlying is at or above its Call Threshold on a Call Observation Date. At maturity, payments depend on the Reference Return of the Worst Performing Underlying, a 50.00% Buffer Amount, and a Downside Leverage Factor of 200%, exposing holders to potential loss of up to 100% of principal (excluding final Interest Payment). The Notes are senior unsecured obligations of Marex and carry Marex credit risk.
Marex Group plc director Assi Georges reported an equity award. On June 9, 2026, he was granted 2,070 Ordinary Shares at a price of $0.00 per share as a restricted share award. The filing notes these awards are contingent rights that convert into one Ordinary Share each upon vesting and settlement, giving him 2,070 shares reported as directly owned after the grant.